Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Alfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion


A Phase 2, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Activity of Alfimeprase in Patients With Acute Peripheral Arterial Occlusion




This trial is for patients with acute occlusion of one of the arteries supplying blood to the leg. The trial is designed to determine the safety and activity of a novel clot dissolving (thrombolytic) drug (alfimeprase).

Study Status: Completed


Condition Intervention Phase
Arterial Occlusive Diseases
Peripheral Vascular Diseases
Drug: Alfimeprase Phase 2

Verified by ARCA Biopharma, Inc. November, 2006

Sponsored by: ARCA Biopharma, Inc.
Information provided by: ARCA Biopharma, Inc. identifier: NCT00073554

Study Type: Interventional

Study Design: Allocation: Randomized, Control: Historical Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Foundation
Cleveland, Ohio
United States


This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site